- Home
- AKRO
as 11-15-2024 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.4B | IPO Year: | 2019 |
| Target Price: | $43.20 | AVG Volume (30 days): | 617.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.41 - $37.00 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yale Catriona | AKRO | Chief Development Officer | Nov 6 '24 | Sell | $35.19 | 10,000 | $351,890.00 | 74,158 | |
| Cheng Andrew | AKRO | President and CEO | Nov 1 '24 | Sell | $31.99 | 108,366 | $3,438,312.07 | 605,417 | |
| Cheng Andrew | AKRO | President and CEO | Oct 16 '24 | Sell | $31.48 | 91,634 | $2,878,038.14 | 605,417 | |
| Young Jonathan | AKRO | Chief Operating Officer | Oct 1 '24 | Sell | $28.18 | 10,000 | $281,770.00 | 226,286 | |
| Yale Catriona | AKRO | Chief Development Officer | Sep 19 '24 | Sell | $27.65 | 5,500 | $152,086.00 | 74,158 | |
| Yale Catriona | AKRO | Chief Development Officer | Sep 16 '24 | Sell | $27.54 | 8,393 | $231,174.81 | 74,158 | |
| Young Jonathan | AKRO | Chief Operating Officer | Sep 13 '24 | Sell | $26.18 | 568 | $14,870.24 | 226,286 | |
| White William Richard | AKRO | Chief Financial Officer | Sep 10 '24 | Sell | $26.18 | 639 | $16,729.02 | 41,152 | |
| Cheng Andrew | AKRO | President and CEO | Sep 10 '24 | Sell | $26.18 | 1,738 | $45,500.84 | 605,417 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Sep 10 '24 | Sell | $26.18 | 537 | $14,058.66 | 180,705 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
GlobeNewswire
4 days ago
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
TipRanks
5 days ago
Akero Therapeutics Advances in MASH Treatment Trials
MT Newswires
9 days ago
Akero Therapeutics' Q3 Net Loss Widens
GlobeNewswire
9 days ago
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
MT Newswires
12 days ago
Akero Therapeutics Insider Sold Shares Worth $3,438,312, According to a Recent SEC Filing
TipRanks
15 days ago
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
GlobeNewswire
a month ago
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.